Trial reportCancer discovery2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Trial report in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 400 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
400 citing papers in PubMed, 2 syntheses or guidelines pooled it, 807 citations in OpenAlex.
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.Nature medicine · 2025Trial
- Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.Investigational new drugs · 2021Trial
- An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.Laboratory investigation; a journal of technical methods and pathology · 2021Trial
- Mechanistic basis of G595R-mediated resistance to entrectinib in TRK kinase: a structural-energetic perspective.Journal of molecular modeling · 2026Article
- Article
- Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases.Cancer research communications · 2026Article
- Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.JTO clinical and research reports · 2026Article
- Review
- Evaluation of the Effects of Nicardipine on Entrectinib Metabolism in vitro and in Rats.European journal of drug metabolism and pharmacokinetics · 2026Article
- Article
- Entrectinib results in ventricular tachycardia and Brugada phenocopy through inhibition of sodium current.Cardio-oncology (London, England) · 2026Article
- Entrectinib-Induced Sinus Bradycardia in a Patient With Metastatic Non-Small Cell Lung Cancer.JACC. Case reports · 2026Article
- Detection of NTRK gene fusions in sarcomas: a comparative study of Pan-TRK immunohistochemistry, FISH, and RNA-Based NGS.Pathologica · 2026Article
- Review
- The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.Nature reviews. Clinical oncology · 2026Review
- TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations.Pathology oncology research : POR · 2026Article
- Diagnostic and Therapeutic Perspectives on Parotid Mammary Analog Secretory Carcinoma: Two Case Reports and Literature Review.Case reports in otolaryngology · 2026Article
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
340 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 3 institutions in 2 countries.
Funding
Abstract
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.